FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a medicinal agent for treating diseases associated with gallbladder and bile ducts, having hepatoprotective properties. Drug is in form of a suspension and contains as active substances 250 or 500 mg of ursodeoxycholic acid (UDCA), 200 or 600 mg of hymecromone and 90 or 270 mg of silymarin, as well as purified water and excipients.
EFFECT: said drug improves bile evacuation, reduces symptomatology of stagnant phenomena, changes qualitative composition of bile, providing a shift from thicker to more liquid, and also has hepatoprotective properties; medicinal agent also has high bioavailability and increased stability.
3 cl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED AGENT CONTAINING UDCA AND HYMECROMONE (EMBODIMENTS) | 2017 |
|
RU2689798C1 |
| PHARMACEUTICAL COMPOSITION BASED ON HEPATOPROTECTOR AND PREBIOTIC AND METHOD FOR PRODUCING AND APPLYING THE COMPOSITION | 2006 |
|
RU2318538C1 |
| HEPATOPROTECTIVE AND ANTIHEPATOTOXIC PHARMACEUTICAL COMPOSITION AND METHOD OF TREATING HEPATIC DISEASES THAT INVOLVES INTRODUCTION OF SAID COMPOSITION | 2008 |
|
RU2381800C1 |
| METHOD OF TREATING PATIENTS SUFFERING FROM FIRST STAGE CHOLELITHIASIS | 2012 |
|
RU2519198C2 |
| METHOD OF PROPHYLAXIS OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH CHOLELITHIASIS AFTER LAPAROSCOPIC CHOLECYSTECTOMY | 2017 |
|
RU2657838C1 |
| METHOD FOR BILIARY SLUDGE TREATMENT IN PATIENTS WITH CHRONIC BILIAR-DEPENDENT PANCREATITIS | 2016 |
|
RU2632443C1 |
| METHOD FOR DEFICIENT BILE REPLACEMENT WITH EXTERNAL BILIARY DRAINAGE | 2013 |
|
RU2532404C1 |
| METHOD OF DOG'S HEPATOSIS THERAPY | 2012 |
|
RU2490018C1 |
| METHOD OF PREDICTING THE EFFECTIVENESS OF LITHOLYSIS IN CHOLELITHIASIS IN COMBINATION WITH NON-ALCOHOLIC FATTY LIVER DISEASE | 2023 |
|
RU2813033C1 |
| METHOD OF TREATING PATIENTS WITH INTESTINAL DYSBACTERIOSIS | 2009 |
|
RU2400235C1 |
